Opiant Pharmaceuticals (OPNT) Stock Analysis

What Opiant Pharmaceuticals does

Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.

Key metrics

ETFs linked to OPNT

Broad-market and Healthcare sector ETFs an investor holding Opiant Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how OPNT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Opiant Pharmaceuticals?

Opiant Pharmaceuticals trades under the ticker OPNT on NASDAQ.

Which exchange is OPNT listed on?

OPNT is listed on NASDAQ.

What sector does Opiant Pharmaceuticals operate in?

Opiant Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze OPNT in a portfolio?

PortView shows OPNT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.